View in EDS

Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.

Saved in:
Bibliographic Details
Title: Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
Authors: Dimopoulos MA; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: mdimop@med.uoa.gr., Hungria VTM; Department of Hematology, Clinica São Germano, São Paulo, Brazil., Radinoff A; Department of Clinical Haematology, University Hospital St Ivan Rilski EAD, Sofia, Bulgaria., Delimpasi S; General Hospital Evangelismos, Athens, Greece., Mikala G; Department of Hematology and Stem Cell Transplantation, South Pest Central Hospital, National Institute for Haematology and Infectious Diseases, Budapest, Hungary., Masszi T; Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary., Li J; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China., Capra M; Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil., Maiolino A; Instituto Americas de Ensino, Pesquisa e Inovacao, Rio de Janeiro, Brazil., Pappa V; Second Department of Internal Medicine and Research Unit, Haematology Unit, University General Hospital Attikon, Athens, Greece., Chraniuk D; Department of Haematology, Wojewodzki Szpital Zespolony, Torun, Poland., Osipov I; VA Almazov National Medical Research Centre, Saint Petersburg, Russia., Leleu X; Haematology, PRC, CHU Poitiers, Poitiers, France., Low M; Monash Haematology, Monash Health, Monash University, Clayton Campus, Clayton VIC, Australia., Matsumoto M; Department of Hematology, Shibukawa Medical Center, Shibukawa, Japan., Sule N; Oncology Clinical Development, GSK, Upper Providence, PA, USA., Li M; Oncology Clinical Development, GSK, Upper Providence, PA, USA., McKeown A; Oncology Clinical Development, GSK, Stevenage, UK., He W; Oncology Biostatistics, GSK, Waltham, MA, USA., Bright S; Pharmacovigilance, GSK, Upper Providence, PA, USA., Currie B; Patients Centered Outcomes, GSK, Rockville, MD, USA., Perera S; Value Evidence and Outcomes, GSK, London, UK., Boyle J; Global Clinical Operations, GSK, London, UK., Roy-Ghanta S; Oncology Clinical Development, GSK, Upper Providence, PA, USA., Opalinska J; Oncology Clinical Development, GSK, Upper Providence, PA, USA., Weisel K; University Medical Center of Hamburg-Eppendorf, Hamburg, Germany.
Source: The Lancet. Haematology [Lancet Haematol] 2023 Oct; Vol. 10 (10), pp. e801-e812.
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 37793771
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Dimopoulos+MA%22">Dimopoulos MA</searchLink>; Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece. Electronic address: mdimop@med.uoa.gr.<br /><searchLink fieldCode="AU" term="%22Hungria+VTM%22">Hungria VTM</searchLink>; Department of Hematology, Clinica São Germano, São Paulo, Brazil.<br /><searchLink fieldCode="AU" term="%22Radinoff+A%22">Radinoff A</searchLink>; Department of Clinical Haematology, University Hospital St Ivan Rilski EAD, Sofia, Bulgaria.<br /><searchLink fieldCode="AU" term="%22Delimpasi+S%22">Delimpasi S</searchLink>; General Hospital Evangelismos, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Mikala+G%22">Mikala G</searchLink>; Department of Hematology and Stem Cell Transplantation, South Pest Central Hospital, National Institute for Haematology and Infectious Diseases, Budapest, Hungary.<br /><searchLink fieldCode="AU" term="%22Masszi+T%22">Masszi T</searchLink>; Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.<br /><searchLink fieldCode="AU" term="%22Li+J%22">Li J</searchLink>; Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.<br /><searchLink fieldCode="AU" term="%22Capra+M%22">Capra M</searchLink>; Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil.<br /><searchLink fieldCode="AU" term="%22Maiolino+A%22">Maiolino A</searchLink>; Instituto Americas de Ensino, Pesquisa e Inovacao, Rio de Janeiro, Brazil.<br /><searchLink fieldCode="AU" term="%22Pappa+V%22">Pappa V</searchLink>; Second Department of Internal Medicine and Research Unit, Haematology Unit, University General Hospital Attikon, Athens, Greece.<br /><searchLink fieldCode="AU" term="%22Chraniuk+D%22">Chraniuk D</searchLink>; Department of Haematology, Wojewodzki Szpital Zespolony, Torun, Poland.<br /><searchLink fieldCode="AU" term="%22Osipov+I%22">Osipov I</searchLink>; VA Almazov National Medical Research Centre, Saint Petersburg, Russia.<br /><searchLink fieldCode="AU" term="%22Leleu+X%22">Leleu X</searchLink>; Haematology, PRC, CHU Poitiers, Poitiers, France.<br /><searchLink fieldCode="AU" term="%22Low+M%22">Low M</searchLink>; Monash Haematology, Monash Health, Monash University, Clayton Campus, Clayton VIC, Australia.<br /><searchLink fieldCode="AU" term="%22Matsumoto+M%22">Matsumoto M</searchLink>; Department of Hematology, Shibukawa Medical Center, Shibukawa, Japan.<br /><searchLink fieldCode="AU" term="%22Sule+N%22">Sule N</searchLink>; Oncology Clinical Development, GSK, Upper Providence, PA, USA.<br /><searchLink fieldCode="AU" term="%22Li+M%22">Li M</searchLink>; Oncology Clinical Development, GSK, Upper Providence, PA, USA.<br /><searchLink fieldCode="AU" term="%22McKeown+A%22">McKeown A</searchLink>; Oncology Clinical Development, GSK, Stevenage, UK.<br /><searchLink fieldCode="AU" term="%22He+W%22">He W</searchLink>; Oncology Biostatistics, GSK, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Bright+S%22">Bright S</searchLink>; Pharmacovigilance, GSK, Upper Providence, PA, USA.<br /><searchLink fieldCode="AU" term="%22Currie+B%22">Currie B</searchLink>; Patients Centered Outcomes, GSK, Rockville, MD, USA.<br /><searchLink fieldCode="AU" term="%22Perera+S%22">Perera S</searchLink>; Value Evidence and Outcomes, GSK, London, UK.<br /><searchLink fieldCode="AU" term="%22Boyle+J%22">Boyle J</searchLink>; Global Clinical Operations, GSK, London, UK.<br /><searchLink fieldCode="AU" term="%22Roy-Ghanta+S%22">Roy-Ghanta S</searchLink>; Oncology Clinical Development, GSK, Upper Providence, PA, USA.<br /><searchLink fieldCode="AU" term="%22Opalinska+J%22">Opalinska J</searchLink>; Oncology Clinical Development, GSK, Upper Providence, PA, USA.<br /><searchLink fieldCode="AU" term="%22Weisel+K%22">Weisel K</searchLink>; University Medical Center of Hamburg-Eppendorf, Hamburg, Germany.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101643584%22">The Lancet. Haematology</searchLink> [Lancet Haematol] 2023 Oct; Vol. 10 (10), pp. e801-e812.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Ltd%22">Elsevier Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101643584 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>2352-3026 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2223523026%22">23523026 </searchLink><i>NLM ISO Abbreviation: </i>Lancet Haematol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=37793771
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1016/S2352-3026(23)00243-0
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e801
    Titles:
      – TitleFull: Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Dimopoulos MA
      – PersonEntity:
          Name:
            NameFull: Hungria VTM
      – PersonEntity:
          Name:
            NameFull: Radinoff A
      – PersonEntity:
          Name:
            NameFull: Delimpasi S
      – PersonEntity:
          Name:
            NameFull: Mikala G
      – PersonEntity:
          Name:
            NameFull: Masszi T
      – PersonEntity:
          Name:
            NameFull: Li J
      – PersonEntity:
          Name:
            NameFull: Capra M
      – PersonEntity:
          Name:
            NameFull: Maiolino A
      – PersonEntity:
          Name:
            NameFull: Pappa V
      – PersonEntity:
          Name:
            NameFull: Chraniuk D
      – PersonEntity:
          Name:
            NameFull: Osipov I
      – PersonEntity:
          Name:
            NameFull: Leleu X
      – PersonEntity:
          Name:
            NameFull: Low M
      – PersonEntity:
          Name:
            NameFull: Matsumoto M
      – PersonEntity:
          Name:
            NameFull: Sule N
      – PersonEntity:
          Name:
            NameFull: Li M
      – PersonEntity:
          Name:
            NameFull: McKeown A
      – PersonEntity:
          Name:
            NameFull: He W
      – PersonEntity:
          Name:
            NameFull: Bright S
      – PersonEntity:
          Name:
            NameFull: Currie B
      – PersonEntity:
          Name:
            NameFull: Perera S
      – PersonEntity:
          Name:
            NameFull: Boyle J
      – PersonEntity:
          Name:
            NameFull: Roy-Ghanta S
      – PersonEntity:
          Name:
            NameFull: Opalinska J
      – PersonEntity:
          Name:
            NameFull: Weisel K
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 10
              Text: 2023 Oct
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 2352-3026
          Numbering:
            – Type: volume
              Value: 10
            – Type: issue
              Value: 10
          Titles:
            – TitleFull: The Lancet. Haematology
              Type: main
ResultId 1